MYnd Analytics (NASDAQ: MYND) positions itself as a technology-driven behavioral health company aiming to solve the high failure rates of psychiatric prescribing. The deck outlines a two-part solution: PEER Online, an AI-driven clinical decision support tool that uses EEG data to predict medication response, and Arcadian Telepsychiatry, a provider network. By targeting the 'ABC’s'—Access, Better Care, and Costs—the company seeks to capture a share of the global behavioral health software market projected to reach $4.31B by 2025. While the deck provides strong clinical validation through docto…
Key takeaways
- The company addresses a massive efficacy gap where only 2.7% of the depressed population achieves remission (Slide 4).
- MYnd claims their PEER Online tool provides a greater than 80% probability of prescribing the correct medication at first treatment (Slide 7).
- The business model is built on a database of 40,000 data points used to compare patient EEG scans (Slide 10).
- The company has secured FDA breakthrough device status for its PEER Online solution (Slide 19).
- Strategic partnerships include Sanford Health and Memorial Hospital Gulfport for telepsychiatry services (Slide 19).
- The deck highlights a significant economic burden, citing over $31B in annual lost productivity due to depression (Slide 4).
- The presentation omits a dedicated team slide, though it lists the Chairman, CEO, and CFO on the final contact page (Slide 25).
- There is no explicit 'Ask' slide detailing the amount of capital being raised or the intended use of funds.
Executive Summary: The Data-Driven Approach to Mental Health
MYnd Analytics presents a case for 'Precision Psychiatry.' The presentation, dated June 2019, targets investors on the NASDAQ (ticker: MYND) by framing behavioral health not just as a medical crisis, but as a data problem. The deck focuses on the inefficiency of current treatment models, where trial-and-error prescribing leads to low remission rates and high costs for payers and employers. By combining an AI-based diagnostic tool with a telepsychiatry service, MYnd attempts to offer a full-stack solution for primary care providers who are often the first line of defense in mental health but lack specialized tools.
Slide 1: Title and Positioning
The cover slide establishes MYnd Analytics as a behavioral health company focused on tools and technology. The subtitle explicitly states the value proposition: improving access to care and reducing trial-and-error prescribing to improve outcomes and lower costs. The inclusion of the NASDAQ ticker immediately signals that this is a public company presentation, likely intended for institutional investors or retail shareholders following a specific earnings period or corporate milestone.
Slide 4: The Behavioral Health Crisis
This slide uses a funnel graphic to illustrate the massive drop-off in effective mental health treatment. It notes that while 90 million people in the U.S. suffer from depression, only 27% receive treatment, and a staggering 2.7% of the total depressed population achieves remission. The slide cites a $31B loss in annual productivity and a projected $4.31B market size for mental health software by 2025. This sets the 'Problem' stage by highlighting both the human cost and the commercial opportunity.
Slide 7: The ABC’s of Behavioral Health
MYnd breaks its solution into three categories: Access, Better Care, and Costs. Access is solved via Arcadian Telepsychiatry’s national network. Better Care is addressed through PEER Online, which the slide claims has a 'greater than 80% probability' of identifying the right medication at first treatment, based on internal data (0.81 sensitivity/0.85 specificity). Costs are reduced by eliminating the visits and prescriptions associated with failed trial-and-error cycles. The slide effectively maps these solutions to three distinct stakeholders: Patients, Health Systems, and Payers.
Slide 10: PEER Online Workflow
This slide explains the technical process of the PEER Online tool. It follows a six-step linear path: 1. EEG scan at a primary care office; 2. Secure upload to PEER Online; 3. Comparison against 40,000 data points; 4. Generation of an AI-driven report; 5. Consultation with a MYnd psychiatrist; 6. Creation of a personalized treatment plan. This visualization is crucial for investors to understand how a complex AI/biotech product actually integrates into a standard doctor's visit.
Slide 13: Clinical Validation and Testimonials
Rather than showing raw data tables, Slide 13 uses 'What Doctors Say' to build credibility. It features quotes from high-profile figures, including the Chief of Clinical Pathology at Quest Diagnostics and a professor from Stanford University School of Medicine. The quotes emphasize the need for objective measures in psychiatry, comparing the brain to other organs that are routinely measured before treatment. This slide serves as a powerful form of social proof for a technology that might otherwise seem experimental to conservative investors.
Slide 16: The Integrated Service Model
This slide illustrates the 'Differentiated Behavioral Health Technology and Services' model. It shows how a patient moves from identification in a primary care clinic to either a PEER-informed treatment plan, telepsychiatry for complex cases, or flexible tele-therapy. By showing these three paths, MYnd demonstrates that it isn't just a software company; it is a service provider capable of handling varying levels of patient acuity.
Slide 19: Recent Developments and Scalability
Slide 19 lists five key milestones intended to show momentum. These include partnerships with Sanford Health and Memorial Hospital Gulfport, and a nationwide expansion for a 'leading EAP provider.' The most significant technical milestone listed is the FDA designated breakthrough device status for PEER Online. This is a critical value inflection point for healthcare investors, as it suggests a cleared regulatory path and recognized clinical novelty.
Slide 22: Summary of Value
The summary reiterates the core themes: personalized therapy, greater access, and lower costs. It positions the company as being 'well positioned' to help a wide array of stakeholders, including government and employers. The language here is broad, designed to leave the investor with a sense of the company’s wide-reaching potential across the entire healthcare ecosystem.
Slide 25: Contact and Leadership
The final slide provides contact information for three key executives: Robin L. Smith (Chairman), Patrick Herguth (CEO), and Don D’Ambrosio (CFO). While the deck lacks a traditional 'Team' slide with biographies and past successes, this contact page at least identifies the top-tier management responsible for the company’s strategy.
What MYnd Analytics Does Well
The deck excels at defining a clear, quantifiable problem. By citing the 2.7% remission rate, they make the current standard of care look objectively broken. The use of a simple 'ABC' framework (Access, Better Care, Costs) makes a complex med-tech play easy to digest for generalist investors. Furthermore, the workflow diagram on Slide 10 demystifies the technology, showing that the barrier to entry for a primary care physician is just an EEG scan and an upload.
What is Missing from the Deck
For a public company presentation, there is a surprising lack of hard financial data. There are no slides showing quarterly revenue growth, gross margins for the telepsychiatry business versus the software business, or a balance sheet summary. Additionally, the deck does not address the competitive landscape. While they mention their solution is 'differentiated,' they do not name other telepsychiatry providers or digital health companies like Ginger or Teladoc, which were active in the space in 2019. Finally, the absence of a detailed team slide is a missed opportunity to highlight the clinical and operational pedigree of the leadership team beyond their names and phone numbers.
Founder Takeaways: Lessons from MYnd
Quantify the Failure of the Status Quo: If your product improves an existing process, don't just say it's 'better.' Use statistics to show how poorly the current system performs, as MYnd did with remission rates on Slide 4. · Map Benefits to Every Stakeholder: In healthcare, the person using the tool (doctor), the person benefiting (patient), and the person paying (payer) are often different. Slide 7 is a great example of how to address all three in one view. · Use Workflow Diagrams: For AI or complex backend technologies, show the 'User Journey.' Slide 10 takes the 'black box' of AI and turns it into a familiar six-step clinical process. · Leverage Regulatory Wins: If you have FDA breakthrough status or similar designations, make it a headline. It is one of the strongest de-risking signals you can send to a healthcare investor.
Frequently asked questions
- What is the core technology behind MYnd Analytics?
- The core technology is PEER Online, a clinical decision support tool. It uses an artificial intelligence algorithm to compare a patient's EEG scan against a database of 40,000 data points. This process generates a personalized report to help primary care physicians and psychiatrists choose medications that are most likely to be effective for that specific patient's brain chemistry, reducing the traditional 'trial and error' approach.
- How does the company address the shortage of behavioral health specialists?
- MYnd utilizes its Arcadian Telepsychiatry division to provide a national network of psychiatric providers, therapists, and social workers. This cloud-based system allows primary care clinics to integrate behavioral health into their existing workflows, providing patients with remote access to specialists who can consult on treatment plans informed by the PEER Online data.
- What market size and growth figures does MYnd cite?
- According to Slide 4, the global behavioral/mental health care software and services market is expected to grow at a CAGR of 11.8%. The company projects the market will reach $4.31B by the year 2025. They also note that depression is the leading cause of disability in the US for individuals aged 15 to 44.
- What clinical validation does the deck provide for the PEER report?
- The deck relies heavily on expert testimonials from institutions like Stanford University School of Medicine and Quest Diagnostics. It also mentions internal data showing a greater than 80% probability of successful first-treatment prescribing based on 0.81 sensitivity and 0.85 specificity. Most significantly, Slide 19 notes that the FDA has granted 'breakthrough device status' to the PEER Online solution.
- Is there information on the company's financial health or revenue?
- No. Despite being a NASDAQ-listed company at the time of the presentation, this specific deck omits revenue figures, profit margins, and burn rates. It lists recent developments and partnerships, such as a contract covering 1/8th of New York State with Care Compass Networks, but does not attach dollar values to these milestones.
